Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
NEW YORK, May 11, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC), today announced that the May 7 presentation from Andrew Gengos, President and Chief Executive Officer, is now available for on-demand viewing at VirtualInvestorConferences.com.
LINK: http://VirtualInvestorConferences.com > red "register/ watch presentations" button
ImmunoCellular's presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell vaccine targeting CD133; ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer killing T-cells. To learn more about ImmunoCellular, please visit www.imuc.com.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE ImmunoCellular Therapeutics
For further information: ImmunoCellular Therapeutics, Ltd., Jane Green, 415.348.0010 direct, 415.652.4819 mobile, firstname.lastname@example.org; VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, email@example.com, http://www.imuc.com